Publications & Posters

 

 
 
     
 
 
Publications:
Posters:
 
 
 
     
 
Publications
 
     
 
 

Targeted immunotherapy in Hodgkin lymphoma. Inside Blood comment. Comment on Rothe et al.

   
  Authors: Hutchings M.
Publication details: Publication details: Blood. 2015 Jun 25; 125(26): 3967-8.doi: 10.1182/ blood-2015-05-641712./. >>>
   
 

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.

   
  Authors: Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA
Publication details: MAbs. 2015 May 4;7(3):584-604. doi: 10.1080/19420862.2015.1029216. [PubMed - in process]./. PMID 25875246>>>
   
 

A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

   
  Authors: Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A.
Publication details: Blood. 2015. Jun 25; 125(26): 4024-31. doi: 10.1182/ blood-2014-12-614636. Epub 2015 Apr 17./. PMID:25887777 >>>
   
 

TandAbs: potent and well-manufacturable bi-specific antibodies

   
  Authors: Weichel M, Ellwanger K, Fucek I, Knackmuss SH, Rajkovic E, Reusch U, Wall C, Zhukovsky EA
Publication details: European Pharmaceutical Review 2015 20(1): 27-32 >>>
   
 

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.

   
  Authors: Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Little M, Zhukovsky EA.
Publication details: MAbs. 2014 Mar 26;6(3). / PMID: 24670809 >>>
   
 

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.

   
  Authors: Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Köhl U, Dürkop H, Engert A, von Strandmann EP.
Publication details: Mol Ther. 2013 Apr;21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5./. PMID:23459515 >>>
   
 

T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.

   
  Authors: Pörtner LM, Schönberg K, Hejazi M, Brünnert D, Neumann F, Galonska L, Reusch U, Little M, Haas R, Uhrberg M.
Publication details: Cancer Immunol Immunother. 2012 Oct;61(10):1869-75. / PMID: 22976535 >>>
   
 

RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.

   
  Authors: McAleese F, Eser M.
Publication details: Future Oncol. 2012 Jun;8(6):687-95. / PMID: 22764766 >>>
   
  Alternative antibody formats. In "Recombinant Antibodies for Immunotherapy".
   
  Authors: Le Gall F and Little M.
Editor: Melvyn Little.
Publication details: Publ. Cambridge University Press, 2009. ISBN: 9780521887328 >>>
   
  Recombinant Antibodies for Immunotherapy.
   
  Authors: various
Editor:
Melvyn Little.
Publication details:
Publ. Cambridge University Press, 2009. ISBN: 9780521887328 >>>
   
 
Posters
 
 

AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody
for high affinity NK-cell engagement in multiple myeloma

   
  Authors: Thorsten Gantke, Uwe Reusch, Christian Kellner, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Matthias Peipp and Martin Treder
Publication details: ASCO 2017 AFM26
   
 

EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR+ tumors with and without Ras mutation

   
  Authors: Michael Kluge, Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Michael Weichel, Torsten Haneke, Stefan Knackmuss, Joachim Koch, Martin Treder
Publication details: AACR 2017 – AFM24
   
 

Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A*02MMP1-003/CD3 TandAbs

   
  Authors: Toni Weinschenk, Erich Rajkovic, Uwe Reusch, Michael Weichel, Kristina Ellwanger, Ivica Fucek, Michael Tesar, Dominik Hinz, Vera Molkenthin, Sebastian Bunk, Norbert Hilf, Oliver Schoor, Dominik Maurer, Kerstin Mock, Carsten Reinhardt, Martin Treder
Publication details: AACR 2017 – MHC
   
 

AFM26 - A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma

   
  Authors: Thorsten Gantke, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Martin Treder
Publication details: AACR 2017 – AFM26
   
 

Trispecific Antibodies for Selective CD16A-directed NK-Cell Engagement
in Multiple Myeloma

   
  Authors: Thorsten Gantke, Michael Weichel, Carmen Herbrecht, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Remko Griep, Vera Molkenthin, Martin Treder
Publication details: ASH 2016 – Trispecific Abs
   
 

Functional Defects of NHL Patients’ T-Cells after Different Chemotherapy Regimens
Activated By CD19/CD3 Tetravalent Bispecific TandAb® AFM11

   
  Authors: Johannes Düll, Dragana Slavkovic, Margarete Karg, Uwe Reusch, Florian Eisele, Jens-Peter Marschner, Hermann Einsele, Martin Treder and Max S. Topp
Publication details: ASH 2016 – AFM11
   
 

AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical
Development Substantially Enhancing NK-Cell Effector Function and Proliferation

   
  Authors: Jens Pahl, Uwe Reusch, Thorsten Gantke, Anne Kerber, Joachim Koch, Martin Treder and Adelheid Cerwenka
Publication details: ASH 2016 – AFM13
   
 

T- or NK-cell recruiting anti-EGFRvIII TandAbs are highly specific and potent
therapeutic antibody candidates for the treatment of EGFRvIII+ tumors

   
  Authors: Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Michael Weichel, Thorsten Gantke, Stefan Knackmuss, Michael Tesar, Martin Treder
Publication details: AACR 2016
   
 

Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NKcells
to potently kill various types of solid tumors

   
  Authors: Kristina Ellwanger, Uwe Reusch, Michael Weichel, Erich Rajkovic, Michael Kluge, Martin Treder
Publication details: AACR 2016
   
 

Immune checkpoint inhibition by anti-PD-1 or CD137 co-stimulation enhances cytotoxicity
towards CD30+ tumors mediated by the bispecific tetravalent CD30/CD16A TandAb AFM13

   
  Authors: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Jens-Peter Marschner, Martin Treder, Holbrook Edwin Kohrt
Publication details: AACR 2016
   
 

CD30/CD16A TandAb AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation And Blocking PD-1

   
  Authors: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Jens-Peter Marschner, Martin Treder, Holbrook Edwin Kohrt
Publication details: ASH 2015
   
 

In Vitro and in Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL and ALL

   
  Authors: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Michael Weichel, Kristina Ellwanger, Jens-Peter Marschner, Martin Treder, Holbrook Edwin Kohrt
Publication details: ASH 2015
   
 

Anti-PD-1 immune checkpoint inhibition or CD137 co-stimulation enhances NK cell cytotoxicity towards CD30+ Hodgkin lymphoma induced by CD30/CD16A TandAb AFM13

   
  Authors: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Jens-Peter Marschner, Martin Treder, Holbrook Edwin Kohrt
Publication details: Natural Killer Cell Symposium
   
 

CD137 co-stimulation and blocking PD-1 enhances NK-cell-mediated target cell lysis by CD30/CD16A TandAb AFM13

   
  Authors: Zhao X, Rajasekaran N, Reusch U, Marschner JP, Treder M, Kohrt HE
Publication details: ASCO 2015
   
 

In vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs

   
  Authors: Eissenberg LG, Ritchey JK, Fox J, Reusch U, Knackmuss S, Guenot J, DiPersio JF
Publication details: ASCO 2015
   
 

Development Of A Bispecific Tetravalent CD33/CD3 TandAb For The Treatment of AML

   
  Authors: Reusch U, Ellwanger K, Weichel M, Molkenthin V, Fox JF, Knackmuss S, Fucek I, Rajkovic E, Zhukovsky EA, Guenot J, Treder M
Publication details: ASCO 2015
   
 

Construction and Characterization of Novel CD33/CD3 Tandem Diabodies (TandAbs®) for the Treatment of Acute Myeloid Leukemia (AML)

   
  Authors: Reusch U,Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss S, Zhukovsky EA, Fox JA, Guenot J, Walter RB
Publication details: ASCO 2015
   
 

EGFRvIII T-cell TandAbs are specific and highly potent drug candidates for the treatment of a variety of solid tumors

   
  Authors: Ellwanger K, Reusch U, Fucek I, Weichel M, Knackmuss S, Herbrecht C, Molkenthin V, Treder M
Publication details: CIMT 2015
   
 

Specific NK cell activation to treat relapsed/refractory (r/r) Hodgkin Lymphoma (HL) patients – final, updated data on clinical outcome, pharmacokinetics and pharmacodynamics of a phase 1 study investigating AFM13, a bispecific anti- CD30/CD16A TandAb

   
  Authors: Rothe A, Sasse S, Topp MS, Eichenauer D, von Tresckow B, Hummel HD, Ravic M, Marschner JP, Engert A
Publication details: ASH 2014
   
 

A CD19/CD3 bispecific TandAb, AFM11, recruits T cells to potently and safely kill CD19+ tumor cells in pre-clinical models

   
  Authors: Reusch U, Knackmuss S, Ellwanger K, Herbrecht C, Fucek I, Zhukovsky EA
Publication details: PEGS 2014
   
 
 
 



 
  Impressum Disclaimer